Sh Kang

Cost-Effectiveness Analysis of Atezolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer With Different PD-L1 Expression Status

Guoqiang Liu, Fangjian Shang, Xinchen Wang, 2021, Frontiers in Oncology.

Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis

Wenjie Liu, Peng-Yu Chen, Geng-wei Huo, 2023, Frontiers in Pharmacology.

Cost-effectiveness of adding durvalumab to first-line chemotherapy for extensive-stage small-cell lung cancer in China

Guoqiang Liu, Sh Kang, 2021, Expert review of pharmacoeconomics & outcomes research.

First-Line Treatments for Extensive-Stage Small-Cell Lung Cancer With Immune Checkpoint Inhibitors Plus Chemotherapy: A Network Meta-Analysis and Cost-Effectiveness Analysis

Yue Zhang, Boyuan Zhang, W. Guo, 2022, Frontiers in Oncology.

Cost-effectiveness analysis of atezolizumab plus chemotherapy as first-line treatment for patients with advanced nonsquamous non-small-cell lung cancer in China

Boyuan Zhang, Fangjian Shang, Sh Kang, 2023, Expert review of pharmacoeconomics & outcomes research.

Cost-effectiveness analysis of toripalimab plus chemotherapy for patients with advanced esophageal squamous cell carcinoma in China

Zhen-hua Pan, Sh Kang, Xiaohui Wang, 2023, Expert review of pharmacoeconomics & outcomes research.

Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis

Sh Kang, Jintuo Yin, 2024, Expert review of pharmacoeconomics & outcomes research.